The online version of this article (doi:10.1186/1475-2867-12-34) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
Conceived and designed the experiments: MD, Acquisition of data: MD, Analyzed and interpreted the data: MD, ASBK, MA. Wrote the paper: MD, Critical and intellectual revision of the article contents: ASBK, MA. All authors read and approved the final manuscript.
Nasopharyngeal carcinoma (NPC) is a unique tumour of epithelial origin with a distinct geographical distribution, genetic predisposition and environmental as well as dietary influence as aetiological factors. Standard NPC treatment regimes, such as radiotherapy and concurrent chemotherapy with cytotoxic drugs, can produce undesirable complications often associated with significant toxicity. Here, we report the effects of a widely distributed flavonoid, quercetin, on cell proliferation, apoptosis and cell cycle arrest. The effects of combining quercetin and cisplatin on human NPC cells were explored.
Cell proliferation was monitored by the dynamic, impedance-based cell analyzer (xCELLigence system) and the MTS assay. Ki67 proliferation antigen and fatty acid synthase (FASN) level was examined by Western blotting. Flow cytometry was also carried out to study the effects of quercetin on cell cycle and apoptosis status.
At 100 μM, quercetin inhibited cell proliferation and decreased expression of FASN and Ki67 antigen. Cell cycle analysis revealed a substantial increase in the proportion of cells in the G2/M phase. We also demonstrated the enhanced cytotoxic effects of quercetin treatment in concomitant with the chemotherapeutic drug, cisplatin, in cultured NPC cells. The combination index (CI) value of quercetin-cisplatin combination was < 1, indicating synergism.
Our study showed that quercetin exhibited synergistic effects with cisplatin against NPC cells. Dose-reduction index (DRI) values > 1 implied the possibility of reducing the cisplatin dosage required to treat NPC, with the addition of quercetin. In turn, this could reduce the risk of cisplatin-associated toxicity. The potential of combining quercetin with cisplatin as a chemotherapeutic strategy for treatment of NPC should be explored further.
Authors’ original file for figure 112935_2012_348_MOESM1_ESM.tiff
Authors’ original file for figure 212935_2012_348_MOESM2_ESM.tiff
Authors’ original file for figure 312935_2012_348_MOESM3_ESM.tiff
Authors’ original file for figure 412935_2012_348_MOESM4_ESM.tiff
Authors’ original file for figure 512935_2012_348_MOESM5_ESM.tiff
Authors’ original file for figure 612935_2012_348_MOESM6_ESM.tiff
Authors’ original file for figure 712935_2012_348_MOESM7_ESM.tiff
Sharma H, Sen S, Singh N: Molecular pathways in the chemosensitization of cisplatin by quercetin in human and neck cancer. Cancer Biology & Therapy. 2005, 4: 949-955. 10.4161/cbt.4.9.1908. CrossRef
Yoshida M, Yamamoto M, Nikaido T: Quercetin arrests human leukemic T-cells in late G1 phase of the cell cycle. Cancer Res. 1992, 52: 6676-6681. PubMed
Ferry DR, Smith A, Malkhandi J, Fyfe DW, De Takats PG, Anderson D, Baker J, Kerr DJ: Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996, 2: 659-668. PubMed
Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, Giese N, Moldenhauer G, Wirth T, Büchler MW: Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010, 37: 551-561. PubMed
Lamson DW, Brignall MS: Antioxidants and Cancer III: Quercetin. Alternative Medicine Review. 2000, 5: 196-208. PubMed
Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, Bonanno G, De Vincenzo R, Ferrandina G, Maggiano N, Capelli A, Mancuso S: Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II). Gynecol Oncol. 1992, 45: 13-19. 10.1016/0090-8258(92)90484-Z. CrossRefPubMed
- Quercetin-induced inhibition and synergistic activity with cisplatin – a chemotherapeutic strategy for nasopharyngeal carcinoma cells
Alan SB Khoo
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II